Business News by Timothy Sumer - If ultimately approved, the drug, aducanumab, made by Biogen, would be the first new Alzheimer’s treatment in nearly two decades. Some evidence suggests it slows, but does not stop, cognitive decline.
from NYT > Business https://ift.tt/36bdgdm
via Timothy Sumer
from NYT > Business https://ift.tt/36bdgdm
via Timothy Sumer
Comments
Post a Comment